Latest Conference Articles

November 11th 2022, 5:20pm

SITC Meeting

CTX130, an investigational allogeneic, CRISP/Cas9 gene-edited, anti-CD70 CAR T-cell therapy, was found to be safe with early signs of clinical activity in patients with advanced clear cell renal cell carcinoma, according to findings from the phase 1 COBALT-RCC trial.

November 11th 2022, 5:00pm

LUGPA Annual Meeting

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

November 11th 2022, 5:00pm

LUGPA Annual Meeting

Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.

November 11th 2022, 5:00pm

LUGPA Annual Meeting

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.

November 11th 2022, 4:46pm

LUGPA Annual Meeting

David Albala, MD, discusses integrating PSMA-PET imaging into the clinic and determining which patients with prostate cancer are prime candidates.

November 11th 2022, 3:45pm

SITC Meeting

The first-line combination of pembrolizumab and eftilagimod alpha elicited a 40.4% (95% CI, 31.3%-50.0%) overall response rate by immune RECIST criteria in the intent-to-treat population in patients with advanced non–small cell lung cancer, according to updated findings from the phase 2 TACTI-002 trial.

November 11th 2022, 2:45pm

LUGPA Annual Meeting

Arlene O. Siefker-Radtke, MD, discusses the use of erdafitinib in urothelial carcinoma.

November 11th 2022, 2:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Richard D. Carvajal, MD, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.

November 11th 2022, 2:00pm

LUGPA Annual Meeting

Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.

November 10th 2022, 10:30pm

PER® Chemotherapy Foundation Symposium (CFS)

Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.

November 10th 2022, 10:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Mark G. Kris, MD, discusses the role of atezolizumab in patients with non–small cell lung cancer.

November 10th 2022, 9:00pm

PER® Chemotherapy Foundation Symposium (CFS)

The combination of nivolumab and ipilimumab have shown overall survival benefit in patients with metastatic melanoma, according to long-term follow-up data, and other studies’ results highlight the efficacy and toxicity benefits of different sequences of the combination.

November 10th 2022, 8:50pm

PER® Chemotherapy Foundation Symposium (CFS)

Research in breast cancer has led to remarkable progress in the understanding and management of the disease, but the oncology community can always do more to optimize treatment outcomes for patients.

November 10th 2022, 8:49pm

PER® Chemotherapy Foundation Symposium (CFS)

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

November 10th 2022, 8:30pm

SITC Meeting

A personalized neoantigen-specific and off-the-shelf T cell receptor T-cell therapy utilized through CRISPR gene editing technology demonstrated feasibility and tolerability in 16 patients across multiple tumor types, according to first-in-human phase 1a findings.

November 10th 2022, 3:30pm

PER® Chemotherapy Foundation Symposium (CFS)

Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.

November 10th 2022, 3:20pm

PER® Chemotherapy Foundation Symposium (CFS)

Emerging novel therapies, new stratification factors, and sequencing challenges because of the new classifications for patients with breast cancer will be topics of discussion at the 40th Annual Chemotherapy Foundation Symposium® during the breast cancer sessions.

November 9th 2022, 8:30pm

PER® Chemotherapy Foundation Symposium (CFS)

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line.

November 9th 2022, 8:20pm

PER® Chemotherapy Foundation Symposium (CFS)

The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs for patients with chronic lymphocytic leukemia.

November 9th 2022, 8:00pm

PER® Chemotherapy Foundation Symposium (CFS)

Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.